G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.15 USD
0.00 (0.00%)
Updated Sep 17, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for G1 Therapeutics falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 82 | 145 | 221 | 207 | 269 |
Receivables | 13 | 11 | 6 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 12 | 16 | 3 | 0 | 0 |
Other Current Assets | 8 | 7 | 13 | 9 | 2 |
Total Current Assets | 115 | 180 | 244 | 216 | 271 |
Net Property & Equipment | 1 | 2 | 2 | 2 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 2 | 0 |
Total Assets | 122 | 188 | 254 | 229 | 285 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 7 | 3 | 4 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 22 | 26 | 23 | 16 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 3 | 2 | 3 | 1 |
Total Current Liabilities | 30 | 36 | 28 | 23 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 52 | 77 | 75 | 20 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 86 | 119 | 111 | 51 | 29 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 815 | 801 | 728 | 613 | 592 |
Retained Earnings | -780 | -732 | -584 | -436 | -337 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 35 | 69 | 144 | 177 | 256 |
Total Liabilities & Shareholder's Equity | 122 | 188 | 254 | 229 | 285 |
Total Common Equity | 35 | 69 | 144 | 177 | 256 |
Shares Outstanding | 51.80 | 42.90 | 42.50 | 38.00 | 37.50 |
Book Value Per Share | 0.68 | 1.60 | 3.38 | 4.67 | 6.81 |
Fiscal Year End for G1 Therapeutics falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 61 | 65 | 82 | 94 | 104 |
Receivables | 13 | 12 | 13 | 9 | 13 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 13 | 13 | 12 | 13 | 16 |
Other Current Assets | 5 | 6 | 8 | 9 | 7 |
Total Current Assets | 93 | 96 | 115 | 126 | 140 |
Net Property & Equipment | 1 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 99 | 102 | 122 | 133 | 148 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 4 | 7 | 6 |
Current Portion Long-Term Debt | 11 | 6 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 18 | 22 | 24 | 25 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 4 | 4 | 2 | 3 |
Total Current Liabilities | 38 | 33 | 30 | 34 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 1 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 33 | 37 | 52 | 51 | 51 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 74 | 74 | 86 | 90 | 90 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 820 | 818 | 815 | 812 | 808 |
Retained Earnings | -796 | -790 | -780 | -769 | -751 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 25 | 28 | 35 | 43 | 58 |
Total Liabilities & Shareholder's Equity | 99 | 102 | 122 | 133 | 148 |
Total Common Equity | 25 | 28 | 35 | 43 | 58 |
Shares Outstanding | 52.20 | 52.20 | 51.80 | 51.80 | 51.70 |
Book Value Per Share | 0.47 | 0.53 | 0.68 | 0.83 | 1.11 |